Osimertinib: A Tale of Triumph and Disaster in Lung Cancer Treatment
"Navigating CNS Progression in EGFR-Mutated NSCLC with T790M-Unknown Status"
Treatment strategies for EGFR-mutated non-small cell lung cancer (NSCLC) have significantly improved with the introduction of osimertinib. This third-generation EGFR inhibitor has shown remarkable efficacy, especially in cases where the EGFR T790M mutation is present, indicating resistance to earlier-generation treatments. Detecting this mutation in plasma or tumor samples is typically required before prescribing osimertinib.
However, osimertinib's ability to penetrate the central nervous system (CNS) offers a potential advantage, particularly for patients experiencing disease progression in the brain. This article delves into the complexities of using osimertinib when the T790M mutation status is negative or unknown, presenting two contrasting cases that highlight both the promise and the challenges of this approach.
Drawing from a case study, we share the clinical histories of two patients with CNS-prominent progression under first/second-generation EGFR inhibitors, where documenting the T790M resistance mutation was not possible. These cases illustrate the critical importance of considering osimertinib for CNS involvement, irrespective of T790M status, and underscore the urgent need for its broader availability.
Survival Gains Amid a Persistent Burden
Lung cancer remains a major public-health burden in the United States: 228,058 new lung cancers were reported in 2023, and 128,663 people died from lung cancer in 2024. Prognosis varies substantially by stage at diagnosis, with reported five-year overall survival ranging from 60% to 74% for stage I, 47% to 55% for stage II, and lower rates for more advanced disease. In the ADAURA results, 88% of people receiving adjuvant osimertinib were alive five years after starting treatment, compared with 78% of those receiving a comparator treatment.
Precision Treatment Requires Molecular Confirmation
Osimertinib therapy is intended for patients whose tumors harbor appropriate EGFR alterations confirmed by testing. After progression, standard approaches may include another targeted therapy when a targetable genetic alteration is identified. Its selectivity is substantial: one review reports that osimertinib is approximately 200 times more potent against the T790M mutation than wild-type EGFR, which may minimize skin and gastrointestinal toxicity, but treatment remains constrained by the molecular features of each tumor.
From T790M Targeting to Global Approval
Osimertinib received its first global approval on November 13, 2015, for patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer. The National Cancer Institute likewise reports that it was initially approved in 2015 for some patients whose NSCLC returned after treatment with another EGFR-targeted drug. Historical accounts describe response rates of nearly 70%, while later reports emphasize that resistance can still emerge through changes such as MET amplification, C797S mutation, or transformation.
The Two Sides of Osimertinib: Hope and Frustration
In this report, we delve into two distinct cases of young EGFR-mutated patients facing central nervous system (CNS) progression while on first-generation EGFR tyrosine kinase inhibitors (TKIs). In both instances, attempts to document the presence of the T790M EGFR mutation—typically a prerequisite for osimertinib prescription—proved unsuccessful.
- Case 1: The Triumph. A 49-year-old man with EGFR-mutated lung adenocarcinoma developed brain metastases after initial treatment with gefitinib. When liquid biopsy failed to detect the T790M mutation, his neurological symptoms worsened rapidly. Despite the absence of T790M proof, off-label osimertinib was administered, leading to significant improvement and the ability to walk again.
- Case 2: The Disaster. A 50-year-old woman with EGFR-mutated lung adenocarcinoma experienced miliary brain dissemination. After initial treatment with afatinib and gefitinib, her condition worsened, and brain MRI revealed diffuse metastases. Although approval for off-label osimertinib was obtained, the patient's rapid decline into a coma prevented drug administration, resulting in a fatal outcome.
Expanding Evidence Across Disease Settings
Clinical research continues to evaluate osimertinib as a targeted therapy for NSCLC with EGFR mutations, including the study registered as NCT03586453. A study of patients with central nervous system metastases reported that most patients with T790M-mutated NSCLC responded to osimertinib. In early-stage disease, adjuvant osimertinib produced a clinically meaningful improvement in disease-free survival after surgery, while a separate report found robust responses in NSCLC with uncommon EGFR mutations without unanticipated safety concerns.
Efficacy Does Not Eliminate Resistance
Despite documented efficacy in first- and second-line settings, patients inevitably develop resistance, and one review notes that there is no further clear treatment path in many cases. The resistance literature identifies treatment failure as a continuing limitation rather than a resolved problem. A reported case also found that first-line osimertinib and chemotherapy, followed by erlotinib, failed to halt metastatic disease, illustrating how sequential therapy may still be unable to control progression.
Benefits Depend on the Comparison
In patients with EGFR-mutated NSCLC and leptomeningeal involvement, one comparative study reported that osimertinib was more effective than first-generation EGFR tyrosine kinase inhibitors. However, a 2026 comparison reported higher overall response and disease-control rates with afatinib than with osimertinib, at 70.2% versus 47.2% and 93.7% versus 82.5%, respectively. Separately, osimertinib combined with chemotherapy was reported to produce superior results to osimertinib alone in EGFR-mutated advanced lung cancer.
The Urgency of Access and Future Directions
The contrasting outcomes of these two cases highlight a critical need: prompt availability of osimertinib for patients with EGFR-mutated NSCLC experiencing CNS progression, regardless of their T790M mutation status. The CNS penetration of osimertinib offers a unique therapeutic advantage that should not be overlooked.
A Guideline-Supported Role After Surgery
Osimertinib is recommended by major guidelines in the adjuvant setting for patients with EGFR mutation-positive NSCLC following surgery. This recommendation places the drug within a broader treatment strategy rather than treating it as a universal therapy for every lung cancer. Its appropriate use therefore depends on both EGFR mutation status and the clinical setting, including whether the disease has been surgically treated.
Testing Osimertinib Beyond Established Settings
The LAURA Phase III trial continues to show an improved overall-survival trend for TAGRISSO, the brand name for osimertinib, in unresectable stage III disease. Research has also reported a favorable overall-survival trend after two years of follow-up when osimertinib is combined with chemotherapy. Market analysis projects substantial growth in the EGFR-NSCLC market during the 2022–2036 study period, although the reported market source describes the projection in terms of a significant compound annual growth rate rather than a specific value.
The Unresolved Post-Resistance Problem
Resistance to osimertinib remains a key challenge in EGFR-mutated NSCLC. Although many studies have evaluated treatments after resistance, a clinical review states that there is still no clear answer about the best systemic therapy. Osimertinib is administered orally at a standard dose of 80 mg once daily, and one source reports that steady-state plasma concentrations are reached in approximately 15 days, but practical treatment details do not resolve the broader problem of progression after targeted therapy.
Evidence Beyond Controlled Trials
A 2024 study described itself as the largest real-world investigation of first-line osimertinib for EGFR mutation-positive NSCLC. In a large real-world analysis of atypical EGFR-mutated metastatic NSCLC, osimertinib was reported to provide superior progression-free and overall survival together with improved tolerability. Real-world reports therefore extend the evidence base beyond trial populations, while an additional report found significant disease-free-survival improvement with adjuvant osimertinib in stage IB to IIIA EGFR mutation-positive NSCLC.
As we await the approval and licensing of osimertinib as a first-line treatment option, these experiences serve as a reminder of its potential to offer hope and improve outcomes in challenging cases. The decision to administer osimertinib in T790M-unknown CNS progression requires careful consideration of individual patient factors and the potential risks and benefits.
Ultimately, further research is needed to better understand the mechanisms of resistance and response to osimertinib in T790M-negative or unknown cases. By sharing these experiences, we hope to stimulate discussion and promote a more nuanced approach to treatment decisions in this complex patient population.